Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming

Danila Valmori, Naira E. Souleimanian, Valeria Tosello, Nina Bhardwaj, Sylvia Adams, David O'Neill, Anna Pavlick, Juliet B. Escalon, Crystal M. Cruz, Angelica Angiulli, Francesca Angiulli, Gregory Mears, Susan M. Vogel, Linda Pan, Achim A. Jungbluth, Eric W. Hoffmann, Ralph Venhaus, Gerd Ritter, Lloyd J. Old, Maha Ayyoub

Research output: Contribution to journalArticlepeer-review

265 Scopus citations


The use of recombinant tumor antigen proteins is a realistic approach for the development of generic cancer vaccines, but the potential of this type of vaccines to induce specific CD8+ T cell responses, through in vivo cross-priming, has remained unclear. In this article, we report that repeated vaccination of cancer patients with recombinant NY-ESO-1 protein, Montanide ISA-51, and CpG ODN 7909, a potent stimulator of B cells and T helper type 1 (Th1)-type immunity, resulted in the early induction of specific integrated CD4+ Th cells and antibody responses in most vaccinated patients, followed by the development of later CD8+ T cell responses in a fraction of them. The correlation between antibody and T cell responses, together with the ability of vaccine-induced antibodies to promote in vitro cross-presentation of NY-ESO-1 by dendritic cells to vaccine-induced CD8 + T cells, indicated that elicitation of NY-ESO-1-specific CD8 + T cell responses by cross-priming in vivo was associated with the induction of adequate levels of specific antibodies. Together, our data provide clear evidence of in vivo cross-priming of specific cytotoxic T lymphocytes by a recombinant tumor antigen vaccine, underline the importance of specific antibody induction for the cross-priming to occur, and support the use of this type of formulation for the further development of efficient cancer vaccines.

Original languageEnglish
Pages (from-to)8947-8952
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Issue number21
StatePublished - 22 May 2007
Externally publishedYes


  • Cancer vaccine


Dive into the research topics of 'Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming'. Together they form a unique fingerprint.

Cite this